Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

Rahway, New Jersey-based Merck & Co., Inc. (MRK ... MRK’s underperformance is apparent compared to the iShares U.S. Pharmaceuticals ETF (IHE). The exchange-traded fund has gained about ...

Separately, company executives said they expect an immaterial impact to the company from proposed U.S ... the Rahway, New Jersey, company. For the recently completed fourth quarter, Merck booked ...

Keytruda, also known as pembrolizumab, accounts for the bulk of the Rahway, New Jersey-based pharmaceutical giant's revenue. However, with its U.S. patent exclusivity ending in 2028, Merck (NYSE ...